Figure 4From: A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia Treatment-emergent adverse events experienced by at least 5% of patients (Safety Analysis Set).Back to article page